 GSK raised its full year guidance for the second time in three months as soaring sales of its shingles vaccine, Shingrix, drove bumper third quarter results which comfortably topped City expectations. The FTSE 100 listed company reported a 9 increase in constant currency quarter three sales to 7.83bn, ahead of City expectations of 7.32bn, with adjusted earnings per share of 46.9p, above forecasts of 40.1p. 